Overview

Effect of LY333531 on Vascular and Neural Functions

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
To determine if protein kinase C beta plays a significant role in vascular endothelial dysfunction, small fiber neural dysfunction, and oxidative stress associated with diabetes mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
Chromaderm, Inc.
Collaborator:
Joslin Diabetes Center
Treatments:
Ruboxistaurin